Huberman LabCuring Autism, Epilepsy & Schizophrenia with Stem Cells | Dr. Sergiu Pașca
Andrew Huberman and Dr. Sergiu Pașca on building Miniature Human Brain Circuits To Treat Devastating Psychiatric Disease.
In this episode of Huberman Lab, featuring Andrew Huberman and Dr. Sergiu Pașca, Curing Autism, Epilepsy & Schizophrenia with Stem Cells | Dr. Sergiu Pașca explores building Miniature Human Brain Circuits To Treat Devastating Psychiatric Disease Neuroscientist and psychiatrist Dr. Sergiu Pașca explains how induced pluripotent stem cells, brain organoids, and assembloids are transforming our ability to study and potentially cure severe neurodevelopmental and psychiatric disorders such as profound autism, epilepsy, and schizophrenia.
At a glance
WHAT IT’S REALLY ABOUT
Building Miniature Human Brain Circuits To Treat Devastating Psychiatric Disease
- Neuroscientist and psychiatrist Dr. Sergiu Pașca explains how induced pluripotent stem cells, brain organoids, and assembloids are transforming our ability to study and potentially cure severe neurodevelopmental and psychiatric disorders such as profound autism, epilepsy, and schizophrenia.
- He clarifies what autism is and is not, why its diagnosed prevalence is rising, and why genetics—not vaccines or single environmental factors—currently provide the strongest, most actionable insights.
- Pașca describes how his lab can now recreate patient‑specific human brain circuits in dishes and in animals, track their development over years, and identify precise molecular defects that are invisible in traditional animal models.
- These approaches have already yielded a first‑in‑kind, stem‑cell–based therapeutic candidate for a rare, severe autism‑epilepsy syndrome (Timothy syndrome), with a clinical trial in preparation, while raising new but tractable ethical questions about organoids, transplantation, and future gene and cell therapies.
IDEAS WORTH REMEMBERING
5 ideasAutism is a behaviorally defined, highly heterogeneous set of disorders with strong genetic underpinnings, not a single disease.
Autism currently affects close to 3% of the population and is diagnosed entirely on behavior—there is no biomarker. The spectrum ranges from mildly affected, fully functional individuals to those with profound autism who are nonverbal, have co‑occurring intellectual disability and epilepsy, and require lifelong care. Twin studies and gene discovery over the last 10–15 years show a very high heritability and hundreds of implicated genes (synaptic proteins, ion channels, chromatin regulators, etc.). This complexity means there will not be one “autism cure,” but rather many disease‑specific mechanisms and interventions.
The rise in autism diagnoses is real but cannot yet be fully explained; better diagnostics and shifting categories account for part, but not all, of the increase.
Changes in diagnostic criteria, greater awareness, and diagnostic migration (e.g., cases previously labeled as intellectual disability now classified as autism) have clearly raised recorded prevalence. Yet the high heritability and consistent prevalence across countries (e.g., Scandinavia, Korea, U.S.) and across isolated populations argue against simple explanations like U.S.‑specific chemicals or vaccines. Environmental factors (e.g., historical thalidomide exposure, prematurity, infections) modulate risk, but no single modern environmental cause has strong causal evidence.
iPSC‑derived brain organoids and assembloids allow direct study of living human brain cells and circuits from specific patients, overcoming major limits of animal models.
By reprogramming a patient’s skin cell into an induced pluripotent stem cell (via Yamanaka factors) and then into 2D neurons or 3D organoids, Pașca’s lab can watch human cortical development unfold over months to years in vitro. Organoids respect human developmental timing (e.g., NMDA receptor subunit switch at ~9 months in vitro), indicating intrinsic “timers.” Assembloids, created by fusing region‑specific organoids, self‑organize realistic interactions: inhibitory interneurons migrate into cortex; cortico‑spinal‑muscle circuits generate movement; four‑part somatosensory assembloids process pain signals. These preparations reveal circuit‑level phenotypes that cannot be seen in mouse knock‑outs alone.
Timothy syndrome illustrates how stem‑cell models can demystify a psychiatric disorder down to a single nucleotide change and guide a precise molecular therapy.
Timothy syndrome is caused by a single base mutation in a calcium channel gene expressed in heart and brain, leading to cardiac issues, epilepsy, and profound autism. iPSC‑derived neurons from patients showed prolonged calcium influx; cortical organoids and transplantation into rats revealed dramatic, disease‑specific defects (e.g., markedly smaller pyramidal neurons) that don’t appear in simple 2D cultures. By deeply characterizing the channel’s misprocessing, Pașca’s group designed a short nucleic‑acid therapeutic that rewires splicing/processing of the channel mRNA and rescues every measured cellular phenotype in vitro and in vivo models. A first clinical trial is now in preparation, developed entirely from human stem‑cell models without a traditional animal disease model.
Many current “stem cell therapies” marketed abroad for autism and other brain conditions are scientifically unjustified and potentially dangerous.
Parents are flying children to clinics in South America and parts of Europe for intravenous, intrathecal, or even intracranial “stem cell” infusions of unclear provenance—sometimes their own cells, sometimes umbilical cells, sometimes unknown donor cells. For autism, there is no plausible mechanism by which generic stem cells in the bloodstream would correct distributed, circuit‑level developmental abnormalities in the brain, especially since most administered cells are lineage‑restricted and not competent to become neurons. Risks include infection, immune reactions, and tumorigenesis, with essentially no controlled trials showing disease‑modifying benefit.
WORDS WORTH SAVING
5 quotesAutism is not one disease. It’s more like fever in the 19th century: a behavioral syndrome that will eventually break down into many different biological conditions with different treatments.
— Dr. Sergiu Pașca
The unbearable inaccessibility of the human brain is one of the main reasons we’ve made such slow progress in understanding psychiatric disorders.
— Dr. Sergiu Pașca
What Yamanaka did was almost like biological alchemy: taking a skin cell and turning it back into something like embryonic stem cells.
— Dr. Sergiu Pașca
These cells in organoids keep time. After about nine months in a dish they switch to a postnatal molecular signature, even though there is no birth, no hormones, nothing changing in the medium.
— Dr. Sergiu Pașca
With Timothy syndrome we’ve gone from a point mutation to a detailed molecular mechanism to a candidate therapy that reverses every cellular defect we’ve measured—all using human stem cell models.
— Dr. Sergiu Pașca
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsIn your Timothy syndrome work, what specific in vitro or in vivo phenotype convinced you that the antisense‑like nucleic acid therapy was targeting the true causal mechanism rather than a downstream epiphenomenon?
Neuroscientist and psychiatrist Dr. Sergiu Pașca explains how induced pluripotent stem cells, brain organoids, and assembloids are transforming our ability to study and potentially cure severe neurodevelopmental and psychiatric disorders such as profound autism, epilepsy, and schizophrenia.
Given that organoids track human developmental timing so faithfully, have you seen any conditions where environmental manipulations (e.g., cytokines, hypoxia, hormones) can accelerate, delay, or desynchronize this intrinsic developmental ‘timer’?
He clarifies what autism is and is not, why its diagnosed prevalence is rising, and why genetics—not vaccines or single environmental factors—currently provide the strongest, most actionable insights.
For 22q11.2 deletion syndrome and other variably penetrant mutations, how are you using organoids and assembloids to dissect why some carriers develop schizophrenia or autism while others remain relatively unaffected?
Pașca describes how his lab can now recreate patient‑specific human brain circuits in dishes and in animals, track their development over years, and identify precise molecular defects that are invisible in traditional animal models.
When you transplant human organoids into neonatal rat cortex, what concrete criteria (beyond absence of pain behavior changes) would you use to decide that the level of human–rat integration has become ethically concerning—for example, in terms of learning capacity or altered rat behavior?
These approaches have already yielded a first‑in‑kind, stem‑cell–based therapeutic candidate for a rare, severe autism‑epilepsy syndrome (Timothy syndrome), with a clinical trial in preparation, while raising new but tractable ethical questions about organoids, transplantation, and future gene and cell therapies.
If we eventually can safely and precisely modulate neuronal developmental timing or rejuvenate specific brain circuits using insights from organoids, where do you personally draw the line between treating profound disease and enhancing normal traits such as memory or cognitive speed?
Chapter Breakdown
Defining Autism: Spectrum, Severity, and Genetics
Pașca explains that autism is a behaviorally defined spectrum condition with no biomarker, ranging from high‑functioning individuals to profoundly impaired children requiring lifelong care. He reviews the historical shift from psychoanalytic ‘refrigerator mother’ theories to twin studies demonstrating strong heritability, and he introduces the concept of “profound autism” linked to specific genetic mutations and associated comorbidities.
Sex Differences, Diagnosis, and Questionable Environmental Links
The discussion turns to male–female differences in autism prevalence, potential underdiagnosis in girls, and biological resilience differences in premature infants. Pașca and Huberman then address popular but weakly supported hypotheses about fever, microbiome, vaccines, and environmental toxins, contrasting them with robust genetic evidence.
Why Autism Prevalence is Rising and the Limits of Correlation
Pașca parses the factors behind rising autism rates—broader criteria, diagnostic migration, and service incentives—while emphasizing that they cannot fully account for the increase. Huberman raises examples of contested environmental correlations (influenza in pregnancy, Amish populations, chemicals), and Pașca explains the pitfalls of correlational thinking and the importance of showing reversible causality, which is nearly impossible directly in humans.
Gene Therapy, CRISPR, and Practical Constraints for Brain Disorders
The conversation shifts to gene therapy and CRISPR as conceptual tools for correcting disease‑causing mutations. Pașca outlines different strategies—adding a gene, supplying an enzyme, editing DNA versus targeting RNA—while emphasizing delivery, gene size, immune responses, and timing as major hurdles for treating brain diseases.
Stem Cell Hype vs Reality: Umbilical Banking and Offshore Clinics
Huberman raises common public questions about umbilical cord banking and commercial stem cell therapies offered abroad. Pașca clarifies that umbilical cells are lineage‑restricted and mostly useful for blood diseases, and he strongly criticizes poorly regulated stem cell injections for autism and CNS conditions as lacking biological rationale and proper clinical evidence.
From Yamanaka Factors to Patient‑Specific Neurons
Pașca walks through the revolution started by Shinya Yamanaka: reprogramming adult skin cells into induced pluripotent stem cells using a small set of factors. This bypasses the need for embryonic tissue, resolves major ethical debates, and provides virtually limitless patient‑specific cells to model disease and test interventions.
Organoids: 3D Self‑Organizing Human Brain Tissue in a Dish
Moving beyond 2D neurons, Pașca describes the development of 3D brain organoids: floating spheroids of human neural tissue that self‑organize into layered cortical‑like structures and can be maintained for years. Remarkably, they follow human developmental timelines, including the prenatal–postnatal NMDA receptor subunit switch.
Assembloids: Building Functional Human Brain Circuits
Pașca introduces assembloids—fused organoids that model interactions between brain regions. He recounts naming assembloids with Ben Barres and describes key examples: interneuron migration into cortex, cortico‑spinal‑muscle motor circuits that can drive contractions, and four‑node pain circuits that reveal subtle channelopathy phenotypes.
Transplanting Human Organoids into Rat Brains
To overcome limitations of in vitro environments, Pașca’s team transplants human cortical organoids into neonatal rat somatosensory cortex. The grafts vascularize, expand, and integrate functionally, acquiring more realistic size and morphology and allowing in vivo testing of candidate therapies on human neurons in a living brain context.
Ethics, Language, and Misconceptions About “Mini Brains”
They tackle ethical questions around organoids and chimeras: consent for cell use, animal welfare in transplantation, and the possibility of emergent properties such as learning or sentience. Pașca stresses the importance of precise terminology and notes the community’s efforts to standardize nomenclature and best practices.
Timothy Syndrome: A Prototype Stem‑Cell–Guided Cure
Pașca explains how methodical work on Timothy syndrome, a monogenic calcium channel disorder causing profound autism and epilepsy, led from basic iPSC modeling to an RNA‑based therapeutic candidate. Lubert Stryer’s reaction highlights how this demystifies psychiatric disease by linking behavior to a single nucleotide and a correctable molecular pathway.
Beyond Autism: Epilepsy, Schizophrenia, and Dystonia
Looking forward, Pașca outlines how similar workflows are being applied to genetic epilepsies, high‑risk schizophrenia syndromes like 22q11.2 deletion, and severe movement disorders such as dystonia. Loop assembloids modeling basal ganglia circuits are being built to pinpoint where in the loop mutations act and where therapies should be targeted.
Personal Motivation, Work Ethic, and Closing Reflections
In closing, Pașca reflects on his motivations as a physician‑scientist, his near‑constant engagement with science, and the joy he finds in walking and art. Huberman underscores how Pașca’s work bridges basic biology and real therapies for devastating brain disorders, and they emphasize the need for careful communication as the field advances.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome